BKG-PHARMA ApS
APSDissolvedAdvertising protectionCVR 27959350Dyrehavevej 53B, 2930 KlampenborgForskning og eksperimentel udvikling indenfor bioteknologi· NACE 721100Est. 2004 · 21 years old1 employees
Loading company…
Overview
BKG-PHARMA ApS is a Danish APS based in Klampenborg, operating in the Forskning og eksperimentel udvikling indenfor bioteknologi sector. Incorporated in 2004, the company has 1 employee and reported a gross profit of -DKK 616.4k in its latest annual filing.
Gross profit 2016
-0.6M DKK
−14% vs 2015
EBITDA margin (of gross profit)
100.0 %
+14% vs 2015
Net profit 2016
-18M DKK
-18970% vs 2015
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
-849.9 %
Very weakAmong the 10% lowest rated companies in the industry
20122016
Liquidity ratioCurrent assets ÷ Short-term debt
0.1×
WeakAmong the 30% lowest rated companies in the industry
20122016
Return on assets (ROA)Net profit ÷ Total assets × 100
<−999 %
Very weakAmong the 10% lowest rated companies in the industry
20122016
EBITDA — year on year
DKK thousandsKey figures
Annual report 2016| Gross profit | -0.6M DKK | -14% |
| EBITDA | -0.6M DKK | +14% |
| Net profit | -18M DKK | -18970% |
| Total assets | 0.3M DKK | -98% |
| Equity | -2.7M DKK | -118% |
| Employees | 1 | — |
Company information
Legal name
BKG-PHARMA ApS
CVR number
27959350
Legal form
Anpartsselskab
NACE code
Founded
8 October 2004 · 21 years
Share capital
DKK 1,548,836
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2016-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med bestyrelsesformanden eller af en direktør i forening to bestyrelsesmedlemmer eller af den samlede bestyrelse.
Contact
Address
Dyrehavevej 53B, 2930 Klampenborg
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2016), BKG-PHARMA ApS reported a gross profit of -DKK 616.4k. The figures on this page draw on 5 annual filings covering 2012 to 2016. The bottom line showed a net loss of DKK 18.0m.
At the end of 2016, current assets covered short-term debt 0.1 times.
Financials
Gross profit
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Gross profit | -616 | -715 | -28 | 938 | 837 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -616 | -715 | -28 | 938 | 837 |
| Depreciation & amort. | -17,448 | -0 | -0 | -0 | -0 |
| EBIT | -18,065 | -715 | -28 | 938 | 837 |
| Net financials | -111 | -25 | -35 | -5 | 0 |
| Profit before tax | -18,176 | -740 | -63 | 933 | 837 |
| Tax | -151 | -645 | 2 | 142 | 302 |
| Net profit | -18,025 | -95 | -65 | 792 | 535 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Total assets | 316 | 18,059 | 15,623 | 15,777 | 15,146 |
| Equity | -2,683 | 15,267 | 14,483 | 14,548 | 13,757 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 2,998 | 2,459 | 599 | 690 | 992 |
| Total debt | 2,998 | 2,459 | 599 | 690 | 992 |
Financial ratios
5-year trendEBITDA margin (of gross profit)
<−999 %
20122016
Equity ratio
-849.9 %
Very weakAmong the 10% lowest rated companies in the industry
20122016
Return on equity
—
20122016
Net profit margin (of gross profit)
<−999 %
20122016
Asset turnover (of gross profit)
-1.95×
20122016
Debt / equity
—
20122016
Sector performance
17 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on assets (ROA)Very weak
Among the 10% lowest rated companies in the industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Basic earning power (BEP)Very weak
Among the 10% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Capacity ratioVery weak
Among the 10% lowest rated companies in the industry
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Return on equity (ROE)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on net assets (RONA)Not rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Liquidity
Current ratioWeak
Among the 30% lowest rated companies in the industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioWeak
Among the 30% lowest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioWeak
Among the 40% lowest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Cash conversion ratioVery weak
Among the 20% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Current assets to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Debt & solvency
Solidity ratioVery weak
Among the 10% lowest rated companies in the industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioVery weak
Among the 10% lowest rated companies in the industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Income to debtVery weak
Among the 10% lowest rated companies in the industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtVery weak
Among the 10% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageVery weak
Among the 10% lowest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtStrong
Among the 30% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginVery weak
Among the 10% lowest rated companies in the industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Debt to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Efficiency & development
Equity to contributed capitalVery weak
Among the 10% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 20% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|
Former (2)
CS Founder | Founder | 2004 – 2017 |
BK Management | Management | 2004 – 2017 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|
Former (7)
FK Board of Directors | Board of Directors | 2004 – 2012 |
BK Board of Directors | Board of Directors | 2007 – 2017 |
SV Board of Directors | Board of Directors | 2004 – 2005 |
MS Chairman | Chairman | 2006 – 2014 |
JV Board of Directors | Board of Directors | 2006 – 2014 |
BA Chairman | Chairman | 2004 – 2006 |
RS Chairman | Chairman | 2014 – 2017 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
| Company | 100% | 100% | 2017 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
BKG HOLDING ApS
BKG-PHARMA ApS Board network connections
Board members of BKG-PHARMA ApS also hold positions in 42 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Sten Verland | Board of Directors | 19 companiesMany roles |
| Morten Stadil | Chairman | 11 companiesMany roles |
| Rasmus Schmiegelow | Chairman | 8 companiesMany roles |
| Carsten Schou | Founder | 2 companies |
| Frank Knudsen | Board of Directors | 2 companies |
Frequently asked questions
What is the CVR number of BKG-PHARMA ApS?
BKG-PHARMA ApS is registered with CVR / Virk under CVR 27959350.
What is the gross profit of BKG-PHARMA ApS?
BKG-PHARMA ApS reported a gross profit of -DKK 616.4k in 2016.
How many employees does BKG-PHARMA ApS have?
BKG-PHARMA ApS employs 1 people as of the latest annual report.
Where is BKG-PHARMA ApS headquartered?
BKG-PHARMA ApS's registered address is Dyrehavevej 53B.